NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
- Citation:
- Cancer vol 123 (18) 3494-501
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 7
- Parents:
- 818
- Children:
- None
- Pharmas:
- Sanofi-Aventis, Pfizer
- Grants:
- U10 CA180821, U10 CA180882, U10 CA180790
- Corr. Author:
- Authors:
- Robert R. McWilliams Nathan R. Foster Michelle R. Mahoney Thomas C. Smyrk Joseph A. Murray Matthew M. Ames Elise Horvath Daniel Schneider Timothy J. Hobday Aminah Jatoi Jeffrey P. Meyers Matthew P. Goetz
- Networks:
- LAPS-MN026, METROMIN
- Study
- NCCTG-N0543
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: